Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Effector Therapeutics Inc (EFTR)

Effector Therapeutics Inc (EFTR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,563
  • Shares Outstanding, K 3,687
  • Annual Sales, $ 0 K
  • Annual Income, $ -35,810 K
  • 60-Month Beta 0.52
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade EFTR with:

Options Overview Details

View History
  • Implied Volatility 0.00% ( unch)
  • Historical Volatility 498.00%
  • IV Percentile 0%
  • IV Rank N/A
  • IV High 0.00% on N/A
  • IV Low 0.00% on N/A
  • Put/Call Vol Ratio N/A
  • Today's Volume N/A
  • Volume Avg (30-Day) N/A
  • Put/Call OI Ratio N/A
  • Today's Open Interest N/A
  • Open Int (30-Day) N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -2.16
  • Number of Estimates 2
  • High Estimate -1.98
  • Low Estimate -2.35
  • Prior Year -6.00
  • Growth Rate Est. (year over year) +64.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.6000 +6.25%
on 04/19/24
16.8820 -89.93%
on 04/03/24
-10.5700 (-86.15%)
since 03/19/24
3-Month
1.6000 +6.25%
on 04/19/24
17.7500 -90.42%
on 03/04/24
-8.9200 (-83.99%)
since 01/19/24
52-Week
1.6000 +6.25%
on 04/19/24
37.0000 -95.41%
on 06/06/23
-8.3000 (-83.00%)
since 04/19/23

Most Recent Stories

More News
Biogen (BIIB), Eisai Seek Full Nod for Alzheimer Drug Leqembi

The FDA grants priority review to Biogen (BIIB) and Eisai's sBLA seeking traditional approval of Alzheimer's disease drug, Leqembi. The FDA decision is expected on Jul 6, 2023.

BIIB : 194.38 (+2.03%)
RHHBY : 30.4100 (+1.20%)
LLY : 726.31 (-2.63%)
EFTR : 1.7000 (-4.49%)
Reata (RETA) Stock Jumps as FDA Approves Rare Disease Drug

Skyclarys is the first drug to be approved specifically for the treatment of Friedreich's ataxia and is also Reata Pharmaceuticals' (RETA) first commercial product

PTCT : 25.32 (+2.55%)
RETA : 172.36 (+0.02%)
ETNB : 9.08 (+2.25%)
EFTR : 1.7000 (-4.49%)
Allogene (ALLO) Incurs Narrower-Than-Expected Loss in Q4

Allogene's (ALLO) fourth-quarter earnings beat estimates but sales come in line.

ADMA : 6.27 (+1.13%)
ALLO : 3.47 (+0.29%)
ETNB : 9.08 (+2.25%)
EFTR : 1.7000 (-4.49%)
Mirati's (MRTX) Q4 Loss Narrows, Krazati Records First Sales

Mirati Therapeutics (MRTX) reports a narrower-than-expected Q4 loss and records first sales of Krazati. Stock rises in after-hours trading.

BMY : 48.93 (+1.30%)
MRK : 125.78 (+0.44%)
MRTX : 58.70 (-0.17%)
EFTR : 1.7000 (-4.49%)
BioMarin (BMRN) Q4 Earnings Miss, Sales Beat, Stock Down

BioMarin (BMRN) reports mixed Q4 results as it misses estimates for earnings but beats the same for sales. Its 2023 sales guidance falls short slightly

SNY : 46.30 (+2.00%)
BMRN : 88.63 (-1.60%)
ADMA : 6.27 (+1.13%)
EFTR : 1.7000 (-4.49%)
Moderna (MRNA) Lags on Q4 Earnings, COVID Jab Sales Down Y/Y

Moderna's (MRNA) fourth-quarter earnings and sales miss expectations. Management reiterates guidance to record a minimum of $5 billion from COVID vaccine sales in 2023.

MRK : 125.78 (+0.44%)
VRTX : 394.28 (+0.20%)
MRNA : 101.41 (-0.58%)
EFTR : 1.7000 (-4.49%)
United Therapeutics (UTHR) Q4 Earnings & Sales Miss Estimates

United Therapeutics' (UTHR) fourth-quarter earnings and sales miss estimates. Tyvaso sales continue to drive the company's top line.

MNKD : 4.18 (+2.45%)
LLY : 726.31 (-2.63%)
UTHR : 237.93 (+0.42%)
EFTR : 1.7000 (-4.49%)
CRISPR (CRSP) Q4 Earnings Surpass Estimates, Sales Miss

CRISPR Therapeutics' (CRSP) fourth-quarter 2022 loss is narrower than expected, while sales miss estimates.

VRTX : 394.28 (+0.20%)
ADMA : 6.27 (+1.13%)
CRSP : 55.05 (-1.98%)
EFTR : 1.7000 (-4.49%)
Biogen (BIIB) Beats Q4 Earnings & Sales Estimates, Stock Up

Biogen (BIIB) beats fourth-quarter estimates for earnings and sales. Stock rises in pre-market.

BIIB : 194.38 (+2.03%)
RHHBY : 30.4100 (+1.20%)
RCUS : 14.59 (-1.68%)
EFTR : 1.7000 (-4.49%)
eFFECTOR Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Presented positive interim results at ASCO 2022 from ongoing zotatifin Phase 1/2 dose escalation and expansion trial Appointed Doug Warner, M.D., as...

EFTR : 1.7000 (-4.49%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

eFFECTOR Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on pioneering the development of a new class of oncology drugs referred to as STRIs. eFFECTOR Therapeutics Inc., formerly known as Locust Walk Acquisition Corp., is based in SAN DIEGO.

See More

Key Turning Points

3rd Resistance Point 2.0000
2nd Resistance Point 1.9000
1st Resistance Point 1.8000
Last Price 1.7000
1st Support Level 1.6000
2nd Support Level 1.5000
3rd Support Level 1.4000

See More

52-Week High 37.0000
Fibonacci 61.8% 23.4772
Fibonacci 50% 19.3000
Fibonacci 38.2% 15.1228
Last Price 1.7000
52-Week Low 1.6000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar